CoChat

Differential Risk of Cancer Associated with Glucagon-like Peptide-1 Receptor Agonists: Analysis of Real-world Databases

Wang, Jiasheng, Kim, Chang H. · 2022 · Endocrine Research

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Abstract

Background Glucagon-like peptide 1 receptor agonists (GLP1Ra) are commonly used in type 2 diabetes mellitus (T2DM). However, differential risk of various cancers among GLP1Ra recipients is unknown.Methods We inquired an aggregated electronic health record database, Explorys, and compared the adjusted odds ratio (aOR) of cancers between GLP1Ra and metformin users. Findings were validated in the FDA Adverse Event Reporting System (FDA FAERS).Results From 1/2005 to 6/2019, we identified 619 340 and 64 230 patients in the metformin and GLP1Ra group, respectively. Within 5 years of starting antidiabetic medications, GLP1Ra was associated with significantly lower incident risk of prostate (aOR 0.81, p = .03), lung (aOR 0.81, p = .05), and colon cancer (aOR 0.85, p = .03), while the risk of thyroid cancer was significantly higher (aOR 1.65, p < .01). Similar findings were seen in the FDA FAERS database, where GLP1Ra was associated with lower risk of prostate (aOR 0.72, p = .08), lung (aOR 0.52, p < .01), colon cancer (aOR 0.82, p = .31), and higher risk of thyroid cancer (aOR 4.33, p < .01). In addition, with longer duration of GLP1Ra use, the risk of prostate, lung, and colon cancer further decreased, suggesting an exposure duration–response relationship.Conclusions GLP1Ra is associated with lower risks of prostate, lung, and colon cancer, but higher risk of thyroid cancer.

Overview

Integrity signals

Registry

Crossref · 10.1080/07435800.2021.1955255

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 29 references

Research works printed but not linked: 3

  1. 10.1210/endo.142.2.7983 · doi:10.1210/endo.142.2.7983 · Paper page
  2. Li XN, 2017, Exp Clin Endocrinol Diabetes, 125, 91
  3. Ganini S, 2014, Cancer Prev Res, 72, 1013

Cited by

See all 76

Metadata

Authors
Wang, J., & Kim, C. H.
Affiliations
MetroHealth Medical Center (US)
Corresponding author
Kim, Chang H.
Venue
Endocrine Research
Published
2021-08-30
Volume
47
Issue
1
Pages
18-25
ISSN
  • 0743-5800 (ISSN-L)
  • 1532-4206
OpenAlex
W3197313174
Cited by
74
References
29
Citations by year
2026: 12 · 2025: 24 · 2024: 17 · 2023: 13 · 2022: 7 · 2021: 1
FWCI
2.98
Type
journal article
Language
en
Open access
closed
Locations
  • Endocrine Research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
Keywords
GLP-1 receptor agonists, cancer risk, type 2 diabetes, metformin, prostate cancer, lung cancer, colon cancer, thyroid cancer, adverse drug reactions, exposure duration, drug safety
MeSH terms
Glucagon-Like Peptide-1 Receptor, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Male, Metformin, Neoplasms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Differential Risk of Cancer Associated with Glucagon-like Peptide-1 Receptor Agonists: Analysis of Real-world Databases. https://app.cochat.ai/papers/10.1080/07435800.2021.1955255
The paper
Wang, J., & Kim, C. H. (2022). Differential Risk of Cancer Associated with Glucagon-like Peptide-1 Receptor Agonists: Analysis of Real-world Databases. Endocrine Research. https://doi.org/10.1080/07435800.2021.1955255

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.